EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications

Ying Cao, Li-Qin Mo, Ya-Juan Liu, Zhen Zhang

Frontiers in Oncology · 07.07.2026 · 16

DOI: 10.3389/fonc.2026.1870658 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 07.07.2026. Verfasst von Ying Cao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology (III), Hangzhou Cancer Hospital, Hangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following the approval of the first antibody-drug conjugate (ADC) for solid tumors, the therapeutic landscape in cancer has been revolutionized. Datopotamab deruxtecan (Dato-DXd) is a TROP2-targeting ADC which is composed of a humanized monoclonal antibody and a potent topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Based on data from multiple clinical trials, Dato-DXd has demonstrated compelling efficacy and a manageable safety profile. Herein, we provide an overview of recent published clinical trial data on Dato-DXd across various solid tumors. In addition, we propose future research directions to address critical issues in the clinical application of Dato-DXd, including optimal sequencing strategies with other TROP2-targeting ADCs, approaches to overcome drug resistance, and management of treatment-related adverse events.

Schlagwörter

Stichwörter der Autor:innen

antibody-drug conjugateclinical trialdatopotamab deruxtecansafetysolid tumors

Autor:innen und Institutionen

  • Department of Medical Oncology (III), Hangzhou Cancer Hospital, Hangzhou, China.

Zitieren

APA

Cao, Y., Mo, L. Q., Liu, Y. J., & Zhang, Z. (2026). Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1870658

Vancouver

Cao Y, Mo LQ, Liu YJ, Zhang Z. Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1870658

BibTeX
@article{Cao2026,
  author = {Cao, Ying and Mo, Li-Qin and Liu, Ya-Juan and Zhang, Zhen},
  title = {Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1870658}
}
Kostenlos starten →